Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.55 |
| ▸ | RXRG | P48443 | 7/20 | 0.55 |
| ▸ | RXRB | P28702 | 6/20 | 0.55 |
| ▸ | RARG | P13631 | 9/20 | 0.54 |
| ▸ | RARB | P10826 | 7/20 | 0.54 |
| ▸ | RARA | P10276 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869955 | 0.83 | RXRA (0.52) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6869716 | 0.79 | RXRA (0.47) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6876422 | 0.76 | RXRA (0.66) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6277352 | 0.75 | RXRA (0.51) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6878500 | 0.75 | RXRA (0.46) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL10962664 | 0.74 | RARG (0.71) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL30590586 | 0.74 | RARG (0.71) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6244136 | 0.74 | RXRA (0.62) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6869561 | 0.74 | RARG (0.46) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6870966 | 0.73 | RXRA (0.54) | RXRARXRGRXRBRARGRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263821-A1 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-08-24 | — | — | US | claimed |
| US-20210361652-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | MELIOR PHARMACEUTICALS I, INC. | 2021-11-25 | — | — | US | claimed |
| US-11033548-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2021-06-15 | — | — | US | claimed |
| US-20190321362-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | CAVALRY FUND I LP | 2019-10-24 | — | — | US | claimed |
| US-10251883-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2019-04-09 | — | — | US | claimed |
| US-20180125845-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | CAVALRY FUND I LP | 2018-05-10 | — | — | US | claimed |
| US-9763945-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20160136165-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | CAVALRY FUND I LP | 2016-05-19 | — | — | US | claimed |
| US-8343985-B2 | Methods for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100278804-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2010-11-04 | — | — | US | claimed |
| US-6028052-A | FOR INCREASING GLUCOSE UPTAKE IN ADIPOSE OR MUSCLE TISSUE, COMPRISING THE STEP OF ADMINISTERING TO SAID TISSUE A COMPOSITION COMPRISING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF AN RXR AGONIST | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-02-22 | — | — | US | claimed |
| US-5972881-A | TREATING HYPERTRIGLYCERIDEMIA, NON-INSULIN-DEPENDENT DIABETES MELLITUS USING A RETINOID X RECEPTOR AGONIST ALONE OR IN COMBINATION WITH A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-10-26 | — | — | US | claimed |
| US-12011445-B2 | Prevention of pancreatic cell degeneration | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20230263821-A1 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-08-24 | — | — | US | disclosed |
| US-20230149404-A1 | Treatment Of Adipocytes | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2023-05-18 | — | — | US | disclosed |
| US-11534442-B2 | Treatment of adipocytes | MELIOR PHARMACEUTICALS I, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-5972881-A | TREATING HYPERTRIGLYCERIDEMIA, NON-INSULIN-DEPENDENT DIABETES MELLITUS USING A RETINOID X RECEPTOR AGONIST ALONE OR IN COMBINATION WITH A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1998043081-A1 | TREATMENT OF GASTROINTESTINAL DISEASE WITH PPAR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-10-01 | — | — | WO | disclosed |
| EP-0859608-A1 | TREATING NIDDM WITH RXR AGONISTS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997010819-A1 | TREATING NIDDM WITH RXR AGONISTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033548-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | LYN, FYN, LPL | RXRA 1212/4885RXRG 943/4885RXRB 1230/4885 |
| US-20230149404-A1 | Treatment Of Adipocytes | LIPG, LPL, PNLIP | RXRA 615/4885RXRG 238/4885RXRB 573/4885 |
| US-20210361652-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1211/4885RXRG 950/4885RXRB 1241/4885 |
| US-20180125845-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1212/4885RXRG 943/4885RXRB 1230/4885 |
| US-10251883-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | LYN, FYN, LPL | RXRA 1212/4885RXRG 943/4885RXRB 1230/4885 |
| US-20160136165-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1212/4885RXRG 943/4885RXRB 1230/4885 |
| US-20190321362-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1212/4885RXRG 943/4885RXRB 1230/4885 |
| US-12011445-B2 | Prevention of pancreatic cell degeneration | IAPP, AMY2A, PNLIP | RXRA 1437/4885RXRG 1323/4885RXRB 1322/4885 |
| US-11534442-B2 | Treatment of adipocytes | LIPG, LPL, PNLIP | RXRA 615/4885RXRG 238/4885RXRB 573/4885 |
| US-20100278804-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1212/4885RXRG 943/4885RXRB 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.